Titleist Asset Management LTD. purchased a new stake in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Rating) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 14,000 shares of the biotechnology company’s stock, valued at approximately $132,000.
Several other large investors have also added to or reduced their stakes in the company. Balyasny Asset Management LLC lifted its holdings in Viking Therapeutics by 1.2% during the third quarter. Balyasny Asset Management LLC now owns 2,673,564 shares of the biotechnology company’s stock valued at $7,272,000 after purchasing an additional 30,613 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in Viking Therapeutics during the third quarter valued at approximately $1,325,000. Marshall Wace LLP purchased a new position in Viking Therapeutics during the third quarter valued at approximately $3,638,000. BlackRock Inc. lifted its holdings in Viking Therapeutics by 2.7% during the third quarter. BlackRock Inc. now owns 1,466,256 shares of the biotechnology company’s stock valued at $3,987,000 after purchasing an additional 39,035 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in Viking Therapeutics by 20.8% during the third quarter. Renaissance Technologies LLC now owns 1,046,400 shares of the biotechnology company’s stock valued at $2,846,000 after purchasing an additional 180,200 shares in the last quarter. Hedge funds and other institutional investors own 34.71% of the company’s stock.
Wall Street Analyst Weigh In
Several equities analysts have weighed in on VKTX shares. HC Wainwright reaffirmed a “buy” rating and set a $21.00 price target on shares of Viking Therapeutics in a report on Thursday, February 9th. Oppenheimer boosted their target price on shares of Viking Therapeutics from $17.00 to $20.00 in a report on Thursday, February 23rd. Raymond James boosted their target price on shares of Viking Therapeutics from $11.00 to $12.00 and gave the stock an “outperform” rating in a report on Thursday, February 9th. Maxim Group boosted their target price on shares of Viking Therapeutics from $10.00 to $15.00 and gave the stock a “buy” rating in a report on Monday, December 19th. Finally, Stifel Nicolaus assumed coverage on shares of Viking Therapeutics in a report on Thursday, March 16th. They issued a “buy” rating and a $22.00 target price on the stock. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to MarketBeat, Viking Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.50.
Viking Therapeutics Trading Down 19.3 %
Viking Therapeutics (NASDAQ:VKTX – Get Rating) last posted its quarterly earnings data on Wednesday, February 8th. The biotechnology company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.03). Analysts anticipate that Viking Therapeutics, Inc. will post -0.96 EPS for the current year.
About Viking Therapeutics
Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.
Featured Stories
- Get a free copy of the StockNews.com research report on Viking Therapeutics (VKTX)
- Asana Stock Gap and Crap. Here’s Why
- On Holding AG Sprints Higher on Margin Expansion and Guidance
- Price Growth & Yield: For That Magical Combo, Leave the U.S.
- Game-Changing News For Tesla Investors
- DOW New Hghs Coming Sooner Than Later
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
